Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 11/20 | 0.70 |
| ▸ | PRKCA | P17252 | 9/20 | 0.70 |
| ▸ | PRKCH | P24723 | 8/20 | 0.70 |
| ▸ | PRKCE | Q02156 | 8/20 | 0.70 |
| ▸ | PRKCQ | Q04759 | 8/20 | 0.70 |
| ▸ | PRKCD | Q05655 | 8/20 | 0.70 |
| ▸ | CDK2 | P24941 | 5/20 | 0.51 |
| ▸ | PRKACA | P17612 | 4/20 | 0.51 |
| ▸ | PRKACG | P22612 | 4/20 | 0.51 |
| ▸ | PRKACB | P22694 | 4/20 | 0.51 |
| ▸ | CDK4 | P11802 | 4/20 | 0.51 |
| ▸ | CCND1 | P24385 | 4/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.51 |
| ▸ | PRKCG | P05129 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541633 | 0.82 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3594020 | 0.82 | PRKCB (1.00) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL1027399 | 0.79 | PRKCB (0.74) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3590073 | 0.76 | PRKCB (0.64) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL2834835 | 0.76 | PRKCB (0.74) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL1027500 | 0.75 | PRKCB (0.62) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL8352562 | 0.74 | PRKCB (0.70) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3536117 | 0.73 | PRKCB (0.79) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL14440437 | 0.73 | CAMK2D (0.60) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL3541824 | 0.72 | PRKCB (0.76) | PRKCBPRKCAPRKCHPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | claimed |
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060058356-A1 | Indolylmaleimide derivatives | NOVARTIS AG | 2006-03-16 | — | — | US | disclosed |
| EP-1597250-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058356-A1 | Indolylmaleimide derivatives | GSK3B, GSK3A, GSKIP | PRKCB 11/4885PRKCA 15/4885PRKCH 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.